期刊
JOURNAL OF IMMUNOLOGY
卷 166, 期 9, 页码 5733-5740出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.166.9.5733
关键词
-
类别
资金
- NCI NIH HHS [R01 CA72631-01, U19 CA 72108-02, R01 CA83706-01] Funding Source: Medline
- PHS HHS [5 POL 34582-01] Funding Source: Medline
The potency of naked DNA vaccines is limited by their inability to amplify and spread in vivo. VP22, a HSV-1 protein, has demonstrated the remarkable property of intercellular transport and may thus provide a unique approach for enhancing vaccine potency. Therefore, we created a novel fusion of VP22 with a model Ag, human papillomavirus type 16 E7, in a DNA vaccine that generated enhanced spreading and MHC class I presentation of Ag. These properties led to a dramatic increase in the number of E7-specific CD8(+) T cell precursors in vaccinated mice (around 50-fold) and converted a less effective DNA vaccine into one with significant potency against E7-expressing tumors. In comparison, nonspreading VP22(1-267) mutants failed to enhance vaccine potency. Our data indicated that the potency of DNA vaccines may be dramatically improved through intercellular spreading and enhanced MHC class I presentation of Ag.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据